Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024. – Biotech Investments

2^nd quarter of 2024:

• Sales of EUR 77.8 million (previous year: EUR 60.1 million)
• EBIT before special items of EUR 17.5 million (previous year: EUR 12.0 million)
• Net income of EUR 9.5 million (previous year: EUR 6.2 million)

1^st half of 2024: 

• Sales of EUR 145.4 million (previous year: EUR 118.0 million)
• EBIT before special items of EUR 32.5 million (previous year: EUR 22.6 million)
• Net income of EUR 18.0 million (previous year: EUR 10.9 million) 

Forecast for 2024: 

• Sales of just under EUR 265 million (confirmed)
• EBIT before special items of around EUR 55 million (raised)

Berlin, July 16, 2024. According to preliminary calculations, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of EUR 145.4 million in the first half of 2024 (previous year: EUR 118.0 million). The key figure EBIT before special items, introduced as part of the 2024 forecast, amounted to EUR 32.5 million in the first half of 2024 (previous year: EUR 22.6 million). Net profit, which is only reported here on a comparative basis, increased to EUR 18.0 million (previous year: EUR 10.9 million).

The Executive Board is raising its profit forecast for the current financial year and expects EBIT before special items of around EUR 55 million.

The sales forecast for the current financial year 2024 published on March 22, 2024 remains unchanged. The Executive Board continues to expect sales of just under EUR 265 million.The full figures for the first half of 2024 will be published on August 9, 2024.

Contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com